EUVIMEDEUVIMED entdecken
Crossref

Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling

Ning Li, Ya-Jie Sun, Li-Yun Huang, Rong-Rong Li, Jun-Sheng Zhang, Ai-Hua Qiu, Jing Wang, Lu Yang

Drug Resistance Updates · 2025-01 · 78 · 101161

DOI: 10.1016/j.drup.2024.101161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-01. Verfasst von Ning Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mechanistic Target of Rapamycin Complex 1, Signal Transduction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Planning Project of Fuzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) frequently emerges, and CDK4/6i-containing therapies in triple-negative breast cancer (TNBC) remain to be determined. METHODS: RNA-sequencing, cell viability analysis, immunoblotting, siRNA transfection et al. were used to investigate and verify the resistance mechanism. BALB/c nude mice xenograft models and spontaneous MMTV-PyMT models were used to explore in vivo efficacy. RESULTS: The mTOR pathway was activated in acquired CDK4/6i-resistant cells and inhibition of mTORC1 restored the sensitivity. While fasting-mimicking diet (FMD) enhances the activity of anticancer agents by inhibiting the mTORC1 signaling, we assessed FMD and found that FMD restored the sensitivity of CDK4/6i-resistant cells to abemaciclib and potentiated the anti-tumor activity of CDK4/6i in TNBC. The anti-tumor effects of FMD and/or CDK4/6i were accompanied by the downregulation of S6 phosphorylation. FMD cooperated with CDK4/6i to suppress the levels of IGF1 and RAS. The combination of FMD and abemaciclib also led to a potent inhibition of tumor growth in spontaneous transgenic MMTV-PyMT mouse models. CONCLUSIONS: Our data demonstrate that FMD overcomes resistance and potentiates the anti-tumor effect of CDK4/6i by inhibiting mTORC1 signaling via lowering the levels of IGF1 and RAS, providing the rationale for clinical investigation of a potential FMD-CDK4/6i strategy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Mechanistic Target of Rapamycin Complex 1Signal TransductionInsulin-Like Growth Factor IFastingXenograft Model Antitumor AssaysAnimalsHumansFemaleMiceCell Line, TumorMice, Inbred BALB CDrug Resistance, NeoplasmMice, NudeProtein Kinase InhibitorsBenzimidazolesTriple Negative Breast NeoplasmsBreast NeoplasmsAminopyridines

Stichwörter der Autor:innen

Breast cancerCDK4/6 inhibitorFasting-mimicking dietResistancemTOR

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Mechanistic Target of Rapamycin Complex 1Insulin-Like Growth Factor ICDK4 protein, humanCDK6 protein, humanIGF1 protein, humanProtein Kinase InhibitorsBenzimidazolesabemaciclib

Autor:innen und Institutionen

  • Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Radiotherapy, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Shantou University Medical College, Shanto…
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: wangj@sysucc.org.cn.

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Planning Project of Fuzhou

Zitieren

APA

Li, N., Sun, Y. J., Huang, L. Y., Li, R. R., Zhang, J. S., Qiu, A. H., Wang, J., & Yang, L. (2025). Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling. Drug Resistance Updates, 78, 101161. https://doi.org/10.1016/j.drup.2024.101161

Vancouver

Li N, Sun YJ, Huang LY, Li RR, Zhang JS, Qiu AH, et al. Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling. Drug Resistance Updates. 2025;78:101161. doi:10.1016/j.drup.2024.101161

BibTeX
@article{Li2025,
  author = {Li, Ning and Sun, Ya-Jie and Huang, Li-Yun and Li, Rong-Rong and Zhang, Jun-Sheng and Qiu, Ai-Hua and Wang, Jing and Yang, Lu},
  title = {Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {78},
  pages = {101161},
  doi = {10.1016/j.drup.2024.101161}
}
Kostenlos starten →